Niro Grazia

Si occupa di epatopatie virus correlate e su base autoimmune ed è referente dell'ambulatorio ad esse dedicato. Ė interessata alla ricerca virologica inerente HBV ed HDV; conduce studi su patogenesi, storia naturale e trattamento; partecipa a trial internazionali. Si occupa della determinazione dell'HDV-RNA; assiste i pazienti ricoverati nel reparto di Gastroenterologia.

Informazioni aggiuntive

  • Pubblicazioni Scientifiche:

    Totale pubblicazioni a partire dal 2011: 45


    Anno

    Sherlock’s Diseases of the Liver and Biliary System, Thirteenth Edition. Edited by James S. Dooley, Anna S. F. Lok, 2018; :

    Sherlock's Diseases of the Liver and Biliary System, 13th Edition

    Farci P., Niro G.

    Gastroenterology & Hepatology 2018; 14(6): 342-351

    Current and Future Management of Chronic Hepatitis D

    Farci P, Niro GA


    2017; ():

    Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study.

    Basili S, Raparelli V, Napoleone L, Talerico G, Corazza GR, Perticone F, Sacerdoti D, Andriulli A, Licata A, Pietrangelo A, Picardi A, Raimondo G, Violi F


    2017; ():

    Hepatitis C Virus Clearance in Older Adults.

    Ippolito AM, Iacobellis A, Milella M, Conti F, Messina V, Valvano MR, Niro GA, Morisco F, Barone M, Termite AP, Brancaccio G, Andriulli A


    2017; ():

    Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: The Hepatitis Delta International Network (HDIN).

    Wranke A, Pinheiro Borzacov LM, Parana R, Lobato C, Hamid S, Ceausu E, Dalekos GN, Rizzetto M, Turcanu A, Niro GA, Lubna F, Abbas M, Ingiliz P, Buti M, Ferenci P, Vanwolleghem T, Hayden T, Dashdorj N, Motoc A, Cornberg M, Abbas Z, Yurdaydin C, Manns MP, W


    2017; 45(3): 481-482

    Letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D - authors' reply.

    Niro GA, Smedile A, Andriulli A, Rizzetto M


    2017; 45(9): 1193-1200

    Systematic review: interferon-free regimens for patients with HCV-related Child C cirrhosis.

    Guarino M, Morisco F, Valvano MR, Ippolito AM, Librandi M, Andriulli N, Greco M, Amoruso A, Iacobellis A, Niro G, Caporaso N, Andriulli A


    2016; ():

    Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia.

    Napolitano G, Iacobellis A, Merla A, Niro G, Valvano MR, Terracciano F, Siena D, Caruso M, Ippolito A, Mannuccio PM, Andriulli A


    2016; 65(3): 465-6

    Myrcludex B, a novel therapy for chronic hepatitis D?

    Rizzetto M, Niro GA


    Alimentary pharmacology and therapeutics 2016; ():

    HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response.

    Niro GA, Smedile A, Fontana R, Olivero A, Ciancio A, Valvano MR, Pittaluga F, Coppola N, Wedemeyer H, Zachou K, Marrone A, Fasano M, Lotti G, Andreone P, Iacobellis A, Andriulli A, Rizzetto M


    2016; ():

    Portal vein thrombosis relevance on liver cirrhosis: Italian Venous Thrombotic Events Registry.

    Violi F, Corazza RG, Caldwell SH, Perticone F, Gatta A, Angelico M, Farcomeni A, Masotti M, Napoleone L, Vestri A, Raparelli V, Basili S, PRO-LIVER Collaborators


    2016; 43(1): 174-5

    Letter: cytomegalovirus colitis in a patient treated with ipilimumab for metastatic melanoma.

    Bossa F, Perri F, Niro G, Parente P, Graziano P, Andriulli A


    2015; 6(): 8019

    International genome-wide meta-analysis identifies new primary biliary cirrhosis risk loci and targetable pathogenic pathways.

    Cordell HJ, Han Y, Mells GF, Li Y, Hirschfield GM, Greene CS, Xie G, Juran BD, Zhu D, Qian DC, Floyd JA, Morley KI, Prati D, Lleo A, Cusi D, Canadian-US PBC Consortium, Italian PBC Genetics Study Group, UK-PBC Consortium, Gershwin ME, Anderson CA, Lazarid


    2014; 60 (4): 1102A

    Long-Term HDV-RNA Suppression ? HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy

    Niro G.A., smedile A., Fontana R., Olivero A., Ciancio A., Pittalunga F., Coppola N., Wedemeyer H., Zachou K., Marrone A., Fasano M., Santantonio T., Lotti G., Andriulli A., Rizzetta M.

    2014; 60: S424-s425

    Entecavir effectiveness in naive and nuc experienced patients with chronic hepatitis b and liver cirrhosis: interim analysis of the italian entas cohort study

    E. Porro, A. Di Leo, A. Marzano, G. Brancaccio, S. Maimone, M. Fasano, A. Grasso, F. Bronte, S. Fagiuoli, T. Santantonio, F. Morisco, E. Petrelli, G. Svegliati Baroni, G. Labbadia, L. Badia, Niro GA, M. Vinci, A. Montineri, F. Vinelli, M. Massari, L. Noso

    2014; ():

    Feasibility of pegylated interferon and ribavirin in hepatitis C-related cirrhosis with neutropenia or thrombocytopenia.

    Iacobellis A, Cozzolongo R, Minerva N, Valvano MR, Niro GA, Fontana R, Palmieri O, Ippolito A, Andriulli A


    2013; : S17

    Entecavir (ETV) prophylaxis in inactive HBV carriers who underwent chemotherapy for solid or haematological cancer: interim analysis of a cohort study

    Di Marco V., Angelucci E., Pietrangelo A., Salerno F., Niro G.A., Daniele B., Vinci M., Villa E., on behalf of ChemEt Study

    2013; : S17

    Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B

    Giuberti T., Fasano M., Brancaccio G., Santantonio T., Grasso A., Marzano A., Bronte F., Maimone S., Fagiuoli S., Caporaso N., Petrelli E., Svegliati Baroni G., Labbadia G., Verucchi G., Niro G.A., Pinzello G.B., Montineri A., Vinelli F., Massari M., Noso

    2013; 58: S311

    Entecavir effectiveness in daily clinical practice, interim analysis of the italian master-entas cohort study of patients with chronic Hepatitis B

    Giuberti T., Fasano M., Brancaccio G., Santantonio T., Grasso A., Marzano A., Bronte F., Maimone S., Fagiuoli S., Caporaso N., Petrelli E., Svegliati Baroni G., Labbadia G., Verucchi G., Niro G.A., Pinzello G.B., Montineri A., Vinelli F., Massari M., Noso

    2013; 58: S301

    Efficacy and safety of entecavir (ETV) prophylaxis in inactive HBV carriers who underwent chemotherapy for solid or haematological cancer: interim analysis of a cohort study

    Di Marco V., Angelucci E., Pietrangelo A., Salerno F., Niro G.A., Daniele B., Vinci M., Villa E., ChemEt Study Group of the Associazione Italiana per lo Studio del Fegato (AISF)

    2013; 45: S56

    Hepatitis delta virus (HDV) induces specific DNA methylation events towards malignancy in hepatoma cells

    Benegiamo G., Vinciguerra M., Guarnieri V., Niro G.A., Andriulli A., Pazienza V.

    2013; 36(8): 600-5

    Variations of serum levels of adiponectin and resistin in chronic viral hepatitis.

    Durazzo M, Belci P, Niro G, Collo A, Grisoglio E, Ambrogio V, Spandre M, Fontana R, Gambino R, Cassader M, Bo S


    2013; 108(7): 1112-22

    Mortality risk according to different clinical characteristics of first episode of liver decompensation in cirrhotic patients: a nationwide, prospective, 3-year follow-up study in Italy.

    Bruno S, Saibeni S, Bagnardi V, Vandelli C, De Luca M, Felder M, Fracanzani AL, Prisco C, Vitaliani G, Simone L, Gaeta GB, Stanzione M, Persico M, Furlan C, Stroffolini T, Salerno F, Maisonneuve P, Almasio PL, AISF (Italian Association for the Study of th


    2013; 20(7): 502-9

    Long-term outcome of hepatitis B virus-related Chronic Hepatitis under protracted nucleos(t)ide analogues.

    Niro GA, Ippolito AM, Fontana R, Valvano MR, Gioffreda D, Iacobellis A, Merla A, Durazzo M, Lotti G, Di Mauro L, Andriulli A


    2013; 587(9): 1424-8

    Hepatitis delta virus induces specific DNA methylation processes in Huh-7 liver cancer cells.

    Benegiamo G, Vinciguerra M, Guarnieri V, Niro GA, Andriulli A, Pazienza V


    2013; 51(9): 1707-17

    Advance in molecular diagnostic tools for hepatitis B virus detection.

    Pazienza V, Niro GA, Fontana R, Vinciguerra M, Andriulli A


    2013; 62(2): 290-8

    Randomised study comparing 48 and 96 weeks peginterferon ?-2a therapy in genotype D HBeAg-negative chronic hepatitis B.

    Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M, PegBeLiver Study Group


    2013; 14(3): 179-86

    Pathway-based analysis of primary biliary cirrhosis genome-wide association studies.

    Kar SP, Seldin MF, Chen W, Lu E, Hirschfield GM, Invernizzi P, Heathcote J, Cusi D, the Italian PBC Genetics Study Group, Almasio PL, Alvaro D, Andreone P, Andriulli A, Barlassina C, Benedetti A, Bernuzzi F, Bianchi I, Bragazzi M, Brunetto M, Bruno S, Cal


    2012; ():

    Estimates of HCV-1 Patients Attaining RVR Following Dual Therapy with Peg-Interferon and Ribavirin.

    Andriulli A, Iacobellis A, Valvano MR, Spirito F, Ippolito A, Bossa F, Terracciano F, Fontana R, Niro G


    2012; :

    Epidemiology and diagnosis of hepatitis D virus

    Niro GA, Fontana R, Ippolito AM, Andriulli A

    2012; 21(23): 5209-5221

    Immunochip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants.

    Juran BD, Hirschfield GM, Invernizzi P, Atkinson EJ, Li Y, Xie G, Kosoy R, Ransom M, Sun Y, Bianchi I, Schlicht EM, Lleo A, Coltescu C, Bernuzzi F, Podda M, Lammert C, Shigeta R, Chan LL, Balschun T, Marconi M, Cusi D, Mason AL, Myers RP, Milkiewicz P, Od


    2012; 32(3): 228-36

    Clinical features of hepatitis d.

    Farci P, Niro GA


    2012; 56(6): 1254-8

    HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5years.

    Fasano M, Lampertico P, Marzano A, Di Marco V, Anna Niro G, Brancaccio G, Marengo A, Scotto G, Rossana Brunetto M, Battista Gaeta G, Rizzetto M, Angarano G, Santantonio T


    2012; 56: s174

    Hepatitis Delta Virus upregulates DNMT3B through STAT3 activation in HUH-7 cells

    Benegiamo G, Vinciguerra M, Mazzoccoli G, Guarnieri V, Niro G, Andriulli A, Pazienza V

    2012; 56: s427

    A substantial proportion of naive HCV-1 infected patients with chronic infection may benefit from current standard therapy with PEG-interferon and ribavirin

    Andriulli A, Valvano MR, Spirito F, Ippolito A, Iacobellis A, Bossa F, Terracciano F, Niro G

    2012; 56: S262

    Hemorrhagic complications following invasive procedures in cirrhotic patients with normal or abnormal coagulopathy. A prospective study

    Napolitano G, Valvano MR, Caruso N, Merla A, Lauriola W, Ippolito A, Siena D, Niro G, Florio F, Andriulli A

    Current infectious disease reports 2012; 14(1): 9-14

    Current concept in the pathophysiology of hepatitis delta infection.

    Niro GA, Smedile A


    2011; 54(4): 605A

    Long-Term Outcome Of Liver Disease In Patients With Hbv-Related Chronic Hepatitis Under Protracted Nucleos(T)Ide Analogs

    Niro GA et al.

    2011; 54(4): 1038A

    Hepatitis Delta Virus Exerts An Epigenetic Control Over Hepatitis B Virus Transcription/Replication Activity

    Raffa et al.

    2011; 54(4): 1077A

    Kinetics Of Hdv-Rna And Hepatitis B Surface Antigen In Chronic Delta Hepatitis Under Pegylated Interferon And/Or Nucleoside Analogs Therapy

    Olivero et al.

    2011; 54(4): 611A

    Effectiveness Of Entecavir In Field Practice: Interim Analysis Of The Italian Master-Entas Cohort Study Of Patients With Chronic Hepatitis B

    Giuberti et al.

    2011; 54: S209-S361

    Efficacy and tolerance of tenofovir in suboptimal responders to adv or adv/lam treatment: 96 weeks results of the optib italian multicenter prospective open label stud

    M. Levrero, L. Cimino, P. Lampertico, M. Vigano’, G.B. Gaeta, G. Brancaccio, E. Sagnelli, V. Messina, G. Raimondo, A. Marzano, F. Stefano, G. Niro, T. Santantonio, M. Puoti, V. Di Marco, G. Mazzella, G. Di Costanzo, M. Angelico, B. Testoni, C. Sava’,

    2011; AISF Annual Meeting 43S: S105

    OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance

    M. Levrero, L. Cimino, P. Lampertico, M. Vigano, G.B. Gaeta, G. Brancaccio, E. Sagnelli, V. Messina, G. Raimondo, A. Marzano, S. Fagiuoli, G. Niro, T. Santantonio, M. Puoti, V. Di Marco, G. Mazzella, G.G. Di Costanzo, M. Angelico, S. Pierconti, C. Sava’

    2011; 18(7): e206-11

    Unawareness of HBV infection among inpatients in a Southern Italian hospital.

    Ippolito AM, Niro GA, Fontana R, Lotti G, Gioffreda D, Valvano MR, Iacobellis A, Di Mauro L, Stroffolini T, Andriulli A


    2011; 43 Suppl 1(): S19-24

    Hepatitis delta virus infection: open issues.

    Niro GA, Gioffreda D, Fontana R


    {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}

nuovo-css

webcamlive

Newsletter

Informativa Newsletter
  twitter   facebook   youtube   g plus